Estimated market cap $401.70MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Nov 2, 2026, last close Nov 13, 2026.51.70M shares, shares as of Nov 2, 2026CIK 1401667The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 17 sells
$2.14M sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Puma Biotechnology Inc's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Puma Biotechnology Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
H-1B labor applications at Puma Biotechnology Inc
4 certified in 12 mo
Labor condition applications decided by the Department of Labor, matched to Puma Biotechnology Inc by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
H-1B labor applications decided at Puma Biotechnology Inc by quarter
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
108
59.6% of shares · 42 added
Latest 10-Q
Q3 2026
What changed in Puma Biotechnology Inc's latest quarterly report, compared with the one before.
Filed Nov 9, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
108 funds report PBYI. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 75% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 38.67M reported shares by 51.62M shares, from the company’s SEC filing as of Aug 3, 2026.
161 funds hold the stock.
Q3 2026: 60% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202565%
Q3 202568%
Q4 202570%
Q1 202674%
Q2 202675%
Q3 2026 (so far)60%
Q3 2026. 15 new, 42 added to, 30 trimmed, 68 exited since Q2 2026.
2 of these funds report values in thousands of dollars; their figures are shown in dollars.
Download CSVEvery fund that holds PBYI, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Puma Biotechnology Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
83
—
24.02M
$1.1B
Q3 2013
92
+9
22.93M
$1.2B
Q4 2013
116
+24
27.00M
$2.8B
Q1 2014
138
+22
25.13M
$2.6B
Q2 2014
138
0
26.99M
$1.8B
Q3 2014
184
+46
26.92M
$6.4B
Q4 2014
189
+5
27.15M
$5.1B
Q1 2015
199
+10
29.12M
$6.9B
Q2 2015
198
-1
30.45M
$3.6B
Q3 2015
163
-35
30.71M
$2.3B
Q4 2015
133
-30
32.22M
$2.5B
Q1 2016
118
-15
30.41M
$892.9M
Q2 2016
110
-8
31.81M
$947.7M
Q3 2016
148
+38
29.99M
$2.0B
Q4 2016
128
-20
35.45M
$1.1B
Q1 2017
136
+8
38.85M
$1.4B
Q2 2017
154
+18
35.53M
$3.1B
Q3 2017
171
+17
36.68M
$4.4B
Q4 2017
203
+32
36.20M
$3.6B
Q1 2018
178
-25
35.58M
$2.4B
Q2 2018
174
-4
36.17M
$2.1B
Q3 2018
156
-18
36.37M
$1.7B
Q4 2018
140
-16
35.53M
$723.3M
Q1 2019
158
+18
34.17M
$1.3B
Q2 2019
139
-19
37.27M
$473.9M
Q3 2019
144
+5
36.59M
$394.0M
Q4 2019
133
-11
31.91M
$279.2M
Q1 2020
125
-8
38.97M
$328.7M
Q2 2020
128
+3
35.27M
$367.8M
Q3 2020
128
0
36.12M
$364.4M
Q4 2020
123
-5
35.41M
$363.6M
Q1 2021
118
-5
36.63M
$355.9M
Q2 2021
120
+2
34.76M
$319.3M
Q3 2021
115
-5
32.17M
$225.5M
Q4 2021
102
-13
30.60M
$93.1M
Q1 2022
103
+1
29.86M
$85.9M
Q2 2022
88
-15
27.89M
$79.5M
Q3 2022
83
-5
27.65M
$65.5M
Q4 2022
89
+6
27.50M
$116.3M
Q1 2023
77
-12
27.86M
$86.1M
Q2 2023
68
-9
26.58M
$93.8M
Q3 2023
69
+1
25.71M
$67.6M
Q4 2023
82
+13
27.01M
$117.0M
Q1 2024
93
+11
31.01M
$164.4M
Q2 2024
99
+6
31.00M
$101.0M
Q3 2024
100
+1
29.79M
$76.0M
Q4 2024
112
+12
29.55M
$90.1M
Q1 2025
116
+4
30.43M
$90.1M
Q2 2025
121
+5
32.89M
$112.8M
Q3 2025
132
+11
34.40M
$182.6M
Q4 2025
151
+19
35.35M
$210.2M
Q1 2026
157
+6
37.86M
$241.8M
Q2 2026
161
+4
38.67M
$313.6M
Q3 2026
108
-53
30.83M
$307.0M
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (74587V107). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.